WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H522640
CAS#: 1354041-91-0
Description: IWP-051 is a potent, orally active sGC stimulator (EC50 = 290nM). IWP-051 showed >99% plasma protein binding, high metabolic stability, high permeability, and no efflux in a Caco-2 model of intestinal absorption. IWP-051 achieves good alignment of potency, stability, selectivity, and pharmacodynamic effects while maintaining favorable pharmacokinetic properties with once-daily dosing potential in humans.
Hodoodo Cat#: H522640
Name: IWP-051
CAS#: 1354041-91-0
Chemical Formula: C17H11F2N5O2
Exact Mass: 355.09
Molecular Weight: 355.305
Elemental Analysis: C, 57.47; H, 3.12; F, 10.69; N, 19.71; O, 9.01
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: IWP-051; IWP051; IWP 051.
IUPAC/Chemical Name: 5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4(3H)-one
InChi Key: LIVYVCAUBHXIMI-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H11F2N5O2/c18-11-4-2-1-3-10(11)9-24-15(13-5-6-26-23-13)7-14(22-24)16-20-8-12(19)17(25)21-16/h1-8H,9H2,(H,20,21,25)
SMILES Code: O=C1NC(C2=NN(CC3=CC=CC=C3F)C(C4=NOC=C4)=C2)=NC=C1F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 355.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans Takashi Nakai, Nicholas R. Perl, Timothy C. Barden, Andrew Carvalho, Angelika Fretzen, Peter Germano, G-Yoon J. Im, Hong Jin, Charles Kim, Thomas W.-H. Lee, Kimberly Long, Joel Moore, Jason M. Rohde, Renee Sarno, Chrissie Segal, Erik O. Solberg, Jenny Tobin, Daniel P. Zimmer, and Mark G. Currie Publication Date (Web): February 24, 2016 (Letter) DOI: 10.1021/acsmedchemlett.5b00479
2. BMC Pharmacol Toxicol. 2015; 16(Suppl 1): PMCID: PMC4565103 Discovery of IWP-051, a novel orally bioavailable soluble guanylate cyclase stimulator with sustained and dose-dependent hemodynamic effects Takashi Nakai,1 Nicholas R Perl,1 Rajesh R Iyengar,corresponding author1 Ara Mermerian,1 G-Yoon J Im,1 Thomas W-H Lee,1 Glen R Rennie,1 James Jia,1 Paul A Renhowe,1 Timothy C Barden,1 James E Sheppeck, II,1 Karthik Iyer,1 Joon Jung,1 G Todd Milne,1 Chrissie Segal,1 Kimberly Long,1 Joy Miyashiro,1 Sylvie Bernier,1 Sarah Jacobson,1 Jenny Tobin,1 Courtney Shea,1 Peter Germano,1 Yueh-tyng Chien,1 and Daniel Zimmer1